RenovoRx offers a Trans-Arterial Micro-Perfusion (TAMP™) therapy platform that delivers oncology agents directly to solid tumors via the peripheral vascular system. This targeted approach, utilizing the FDA-cleared RenovoCath® device, aims to increase drug concentration at the tumor site while potentially reducing systemic toxicities.
Funding
$12.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Standard systemic chemotherapy for solid tumor cancers often results in significant toxicities and may be limited in efficacy due to poor tumor vascularization. This approach circulates therapeutic agents throughout the body, potentially leading to off-target effects and reduced drug concentration at the tumor site.
Solution
RenovoRx utilizes its proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to deliver oncology agents directly to tumor sites via the peripheral vascular system. The TAMP platform, enabled by the FDA-cleared RenovoCath® device, creates a localized perfusion zone to bathe the tumor with therapeutic agents. This targeted approach aims to enhance drug efficacy by increasing concentration at the tumor while potentially minimizing systemic toxicities compared to intravenous administration. The company is currently evaluating this platform in a Phase III clinical trial for locally advanced pancreatic cancer.
Target Audience
The primary target audience includes oncologists, interventional radiologists, and clinical researchers focused on solid tumor treatments, particularly those treating pancreatic cancer.
Features
- Proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for localized drug delivery.
- FDA-cleared RenovoCath® device with a dual-balloon design for temporary vessel occlusion and controlled perfusion.
- Enables targeted delivery of therapeutic agents across the arterial wall near the tumor site.
- Designed to potentially minimize systemic toxicities associated with intravenous chemotherapy.
- Currently being evaluated in a Phase III clinical trial (TIGeR-PaC) for locally advanced pancreatic cancer.
- Holds a portfolio of 19 issued patents and 12 pending patents related to its drug delivery technology.
- Orphan Drug Designation for its intra-arterial gemcitabine (IAG) product candidate for pancreatic and bile duct cancers.